US009409983B2

(12) **United States Patent**
Garcia

(10) **Patent No.: US 9,409,983 B2**
(45) **Date of Patent: Aug. 9, 2016**

(54) **METHODS AND COMPOSITIONS INVOLVING PBEF INHIBITORS FOR LUNG INFLAMMATION CONDITIONS AND DISEASES**

(75) Inventor: **Joe G. N. Garcia**, Chicago, IL (US)

(73) Assignee: **The Board of Trustess of the University of Illinois**, Urbana, IL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 401 days.

(21) Appl. No.: **12/842,773**

(22) Filed: **Jul. 23, 2010**

(65) **Prior Publication Data**

US 2011/0020364 A1 Jan. 27, 2011

Related U.S. Application Data

(60) Provisional application No. 61/227,878, filed on Jul. 23, 2009.

(51) **Int. Cl.**

A61K 39/00	(2006.01)
A61K 38/00	(2006.01)
C07K 14/00	(2006.01)
C07K 16/24	(2006.01)
C12N 15/113	(2010.01)

(52) **U.S. Cl.**

CPC ***C07K 16/243*** (2013.01); ***C12N 15/1136*** (2013.01); *A61K 2039/505* (2013.01); *C07K 2317/76* (2013.01); *C12N 2310/14* (2013.01)

(58) **Field of Classification Search**

CPC . A61K 39/00; A61K 39/395; A61K 39/3955; A61K 39/39541; A61K 38/00

USPC 424/158.1; 514/1.1

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,415,723	A	11/1983	Hedges et al.	
4,458,066	A	7/1984	Caruthers et al.	
4,554,101	A	11/1985	Hopp et al.	
4,683,195	A	7/1987	Mullis et al.	
4,683,202	A	7/1987	Mullis et al.	
4,797,368	A	1/1989	Carter et al.	
4,800,159	A	1/1989	Mullis et al.	
4,816,567	A	3/1989	Cabilly et al.	
4,883,750	A	11/1989	Whiteley et al.	
5,139,941	A	8/1992	Muzyczka et al.	
5,187,260	A	2/1993	Karali et al.	
5,194,596	A *	3/1993	Tischer et al.	530/399
5,279,721	A	1/1994	Schmid	
5,350,836	A *	9/1994	Kopchick et al.	530/399
5,795,715	A	8/1998	Livache et al.	
5,840,873	A	11/1998	Nelson et al.	
5,843,640	A	12/1998	Patterson et al.	
5,843,650	A	12/1998	Segev	
5,843,651	A	12/1998	Stimpson et al.	
5,843,663	A	12/1998	Stanley et al.	
5,846,708	A	12/1998	Hollis et al.	
5,846,709	A	12/1998	Segev	
5,846,717	A	12/1998	Brow et al.	
5,846,726	A	12/1998	Nadeau et al.	
5,846,729	A	12/1998	Wu et al.	
5,846,783	A	12/1998	Wu et al.	
5,849,481	A	12/1998	Urdea et al.	
5,849,486	A	12/1998	Heller et al.	
5,849,487	A	12/1998	Hase et al.	
5,849,497	A	12/1998	Steinman	
5,849,546	A	12/1998	Sousa et al.	
5,849,547	A	12/1998	Cleuziat et al.	
5,851,772	A	12/1998	Mirzabekov et al.	
5,853,990	A	12/1998	Winger et al.	
5,853,992	A	12/1998	Glazer et al.	
5,853,993	A	12/1998	Dellinger et al.	
5,856,092	A	1/1999	Dale et al.	
5,858,652	A	1/1999	Laffler et al.	
5,861,244	A	1/1999	Wang et al.	
5,863,732	A	1/1999	Richards	
5,863,753	A	1/1999	Haugland et al.	
5,866,331	A	2/1999	Singer et al.	
5,866,366	A	2/1999	Kallender	
5,882,864	A	3/1999	An et al.	
5,889,136	A	3/1999	Scaringe et al.	
5,900,481	A	5/1999	Lough et al.	
5,905,024	A	5/1999	Mirzabekov et al.	
5,910,407	A	6/1999	Vogelstein et al.	
5,912,124	A	6/1999	Kumar	
5,912,145	A	6/1999	Stanley	

(Continued)

FOREIGN PATENT DOCUMENTS

EP	320 308	6/1989
EP	329 822	8/1989
GB	2 202 328	9/1988
WO	8403564	9/1984
WO	8706270	10/1987
WO	8810315	12/1988

(Continued)

OTHER PUBLICATIONS

Hong et al., (Am J Respir Crit Care Med. Sep. 15, 2008;178(6):605-17. Epub Jul. 24, 2008).*
Ye et al., (Microvascular Res. Sep. 26, 2005. 70:142-151).*
Benjamin et al., 1998, Development 125:1591-1598.*
Vukicevic et al. 1996, PNAS USA 93:9021-9026.*
Massague, 1987, Cell 49:437-8.*
Pilbeam et al., 1993, Bone 14:717-720.*
Skolnick et al. 2000, Trends in Biotech. 18:34-39.*
Bork, 2000, Genome Research 10:398-400.*
Doerks et al., 1998, Trends in Genetics 14:248-250.*

(Continued)

Primary Examiner — Cherie M Stanfield

(74) *Attorney, Agent, or Firm* — McDonnell Boehnen Hulbert & Berghoff LLP

(57) **ABSTRACT**

The present invention concerns methods and compositions involving inhibitors of Pre-B Cell Colony Enhancing Factor (PBEF) for inflammatory conditions and diseases, including acute lung injury (ALI), ventilator-induced lung injury (VILI), and acute respiratory distress syndrome (ARDS). The present invention also concerns biomarkers for inflammation as well as methods for screening for PBEF inhibitors.

11 Claims, 19 Drawing Sheets